How much did Avecho Biotechnology achieve in EBIT for the current year?
In the current year, Avecho Biotechnology has achieved an EBIT of -3.51 M AUD.
Avecho Biotechnology EBIT 2024
Avecho Biotechnology EBIT
-3.51 M AUD
Ticker
AVE.AX
ISIN
AU0000047441
WKN
A2PLEV
In 2024, Avecho Biotechnology's EBIT was -3.51 M AUD, a 43.95% increase from the -2.44 M AUD EBIT recorded in the previous year.
The Avecho Biotechnology EBIT history
| YEAR | EBIT (undefined AUD) |
|---|---|
| 2023 | -3,513.62 |
| 2022 | -2,440.94 |
| 2021 | -3,387.58 |
| 2020 | -2,813.65 |
| 2019 | 973.9 |
| 2018 | -3,828.95 |
| 2017 | -8,727.8 |
| 2016 | -10,117 |
| 2015 | -12,374 |
| 2014 | -8,013 |
| 2013 | -12,660 |
| 2012 | -11,080 |
| 2011 | -11,920 |
| 2010 | -4,370 |
| 2009 | -8,350 |
| 2008 | -8,440 |
| 2007 | -8,720 |
| 2006 | -6,130 |
| 2005 | -4,590 |
| 2004 | -1,450 |
Avecho Biotechnology Revenue, EBIT, Net Income AU0000047441 · A2PLEV
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Avecho Biotechnology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Avecho Biotechnology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Avecho Biotechnology’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Avecho Biotechnology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Avecho Biotechnology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Avecho Biotechnology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Avecho Biotechnology’s growth potential.
Avecho Biotechnology Revenue, EBIT and net profit per share
| Date | Avecho Biotechnology Revenue | Avecho Biotechnology EBIT | Avecho Biotechnology Net Income |
|---|---|---|---|
| 2023 | 473,550 AUD | -3.51 M AUD | -3.44 M AUD |
| 2022 | 1.13 M AUD | -2.44 M AUD | -2.34 M AUD |
| 2021 | 793,600 AUD | -3.39 M AUD | -3.42 M AUD |
| 2020 | 384,630 AUD | -2.81 M AUD | -2.63 M AUD |
| 2019 | 4.24 M AUD | 973,900 AUD | 849,960 AUD |
| 2018 | 1.39 M AUD | -3.83 M AUD | -3.99 M AUD |
| 2017 | 1.15 M AUD | -8.73 M AUD | -8.55 M AUD |
| 2016 | 1.59 M AUD | -10.12 M AUD | -17.31 M AUD |
| 2015 | 2.19 M AUD | -12.37 M AUD | -20.12 M AUD |
| 2014 | 2.05 M AUD | -8.01 M AUD | -8.94 M AUD |
| 2013 | 2.16 M AUD | -12.66 M AUD | -12.67 M AUD |
| 2012 | 2.66 M AUD | -11.08 M AUD | -11.06 M AUD |
| 2011 | 3.17 M AUD | -11.92 M AUD | 1.11 M AUD |
| 2010 | 5.28 M AUD | -4.37 M AUD | -11.28 M AUD |
| 2009 | 1.4 M AUD | -8.35 M AUD | -8.5 M AUD |
| 2008 | 3.25 M AUD | -8.44 M AUD | -91.21 M AUD |
| 2007 | 4.35 M AUD | -8.72 M AUD | -8.84 M AUD |
| 2006 | 3.41 M AUD | -6.13 M AUD | -6.13 M AUD |
| 2005 | 3.31 M AUD | -4.59 M AUD | -7.32 M AUD |
| 2004 | 290,000 AUD | -1.45 M AUD | -3.15 M AUD |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 290,000 AUD | -1.45 M AUD | -3.15 M AUD |
| 2005 | 3.31 M AUD | -4.59 M AUD | -7.32 M AUD |
| 2006 | 3.41 M AUD | -6.13 M AUD | -6.13 M AUD |
| 2007 | 4.35 M AUD | -8.72 M AUD | -8.84 M AUD |
| 2008 | 3.25 M AUD | -8.44 M AUD | -91.21 M AUD |
| 2009 | 1.4 M AUD | -8.35 M AUD | -8.5 M AUD |
| 2010 | 5.28 M AUD | -4.37 M AUD | -11.28 M AUD |
| 2011 | 3.17 M AUD | -11.92 M AUD | 1.11 M AUD |
| 2012 | 2.66 M AUD | -11.08 M AUD | -11.06 M AUD |
| 2013 | 2.16 M AUD | -12.66 M AUD | -12.67 M AUD |
| 2014 | 2.05 M AUD | -8.01 M AUD | -8.94 M AUD |
| 2015 | 2.19 M AUD | -12.37 M AUD | -20.12 M AUD |
| 2016 | 1.59 M AUD | -10.12 M AUD | -17.31 M AUD |
| 2017 | 1.15 M AUD | -8.73 M AUD | -8.55 M AUD |
| 2018 | 1.39 M AUD | -3.83 M AUD | -3.99 M AUD |
| 2019 | 4.24 M AUD | 973,900 AUD | 849,960 AUD |
| 2020 | 384,630 AUD | -2.81 M AUD | -2.63 M AUD |
| 2021 | 793,600 AUD | -3.39 M AUD | -3.42 M AUD |
| 2022 | 1.13 M AUD | -2.44 M AUD | -2.34 M AUD |
| 2023 | 473,550 AUD | -3.51 M AUD | -3.44 M AUD |
Avecho Biotechnology stock margins AU0000047441 · A2PLEV
The Avecho Biotechnology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Avecho Biotechnology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Avecho Biotechnology.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Avecho Biotechnology's sales revenue. A higher gross margin percentage indicates that the Avecho Biotechnology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Avecho Biotechnology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Avecho Biotechnology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Avecho Biotechnology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Avecho Biotechnology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Avecho Biotechnology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Avecho Biotechnology Margin History
| Avecho Biotechnology Gross margin | Avecho Biotechnology Profit margin | Avecho Biotechnology EBIT margin | Avecho Biotechnology Profit margin |
|---|---|---|---|
| 2023 | -9.25 % | -741.97 % | -725.7 % |
| 2022 | 70.23 % | -216.15 % | -207.43 % |
| 2021 | 64 % | -426.86 % | -430.46 % |
| 2020 | 62.63 % | -731.52 % | -685.04 % |
| 2019 | 94.94 % | 22.98 % | 20.06 % |
| 2018 | 60.32 % | -274.62 % | -286.24 % |
| 2017 | 91.85 % | -758.7 % | -742.84 % |
| 2016 | 79.22 % | -637.09 % | -1,090.3 % |
| 2015 | 69.54 % | -565.02 % | -918.72 % |
| 2014 | 77.55 % | -390.31 % | -435.22 % |
| 2013 | 65.28 % | -586.11 % | -586.57 % |
| 2012 | 72.56 % | -416.54 % | -415.79 % |
| 2011 | 67.19 % | -376.03 % | 35.02 % |
| 2010 | 99.24 % | -82.77 % | -213.64 % |
| 2009 | 83.57 % | -596.43 % | -607.14 % |
| 2008 | 96.31 % | -259.69 % | -2,806.46 % |
| 2007 | 98.62 % | -200.46 % | -203.22 % |
| 2006 | 94.13 % | -179.77 % | -179.77 % |
| 2005 | 99.7 % | -138.67 % | -221.15 % |
| 2004 | -9.25 % | -500 % | -1,086.21 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | -9.25 % | -500 % | -1,086.21 % |
| 2005 | 99.7 % | -138.67 % | -221.15 % |
| 2006 | 94.13 % | -179.77 % | -179.77 % |
| 2007 | 98.62 % | -200.46 % | -203.22 % |
| 2008 | 96.31 % | -259.69 % | -2,806.46 % |
| 2009 | 83.57 % | -596.43 % | -607.14 % |
| 2010 | 99.24 % | -82.77 % | -213.64 % |
| 2011 | 67.19 % | -376.03 % | 35.02 % |
| 2012 | 72.56 % | -416.54 % | -415.79 % |
| 2013 | 65.28 % | -586.11 % | -586.57 % |
| 2014 | 77.55 % | -390.31 % | -435.22 % |
| 2015 | 69.54 % | -565.02 % | -918.72 % |
| 2016 | 79.22 % | -637.09 % | -1,090.3 % |
| 2017 | 91.85 % | -758.7 % | -742.84 % |
| 2018 | 60.32 % | -274.62 % | -286.24 % |
| 2019 | 94.94 % | 22.98 % | 20.06 % |
| 2020 | 62.63 % | -731.52 % | -685.04 % |
| 2021 | 64 % | -426.86 % | -430.46 % |
| 2022 | 70.23 % | -216.15 % | -207.43 % |
| 2023 | -9.25 % | -741.97 % | -725.7 % |
Avecho Biotechnology Aktienanalyse
What does Avecho Biotechnology do?
Avecho Biotechnology Ltd is a company specializing in the research of technologies to make active ingredients in the cosmetics industry more effective. The company was founded in 2008 by Dr. Timo Roiko-Jokela and is headquartered in Oxfordshire, England. Avecho's business model is based on the innovation of active ingredient technologies. The company has developed a unique technology called Invisicare® that is able to release active ingredients over a longer period of time, resulting in higher effectiveness in application. This technology also allows for better transportation of the active ingredients through the skin while protecting the skin barrier. Avecho Biotechnology has various divisions that focus on different areas of the cosmetics industry, including skincare, sunscreens, haircare, oral care, and body care. Within these divisions, the company offers various products based on the Invisicare® technology, including creamy lotions, serums, sunscreens, and shampoos. One example product from Avecho is the SolarCare range of sun care products, which are able to protect the skin from the harmful effects of UV rays while moisturizing the skin. Another example is the SkinPep range, which is specifically tailored to the needs of the skin and has high effectiveness due to its unique formula and technology. Avecho's innovations and products are utilized by a variety of cosmetics companies and brands. The company works closely with its customers to develop customized products that are tailored to their individual requirements. In recent times, Avecho has expanded its research and development efforts in the field of dermatology. The company is working to find innovative solutions for skin conditions such as psoriasis, eczema, and acne. The Invisicare® technology from Avecho is a key element in improving the effectiveness of active ingredients and protecting the skin barrier. Overall, Avecho Biotechnology is an innovative company specializing in the development of technologies and products in the cosmetics and dermatology industry. With its unique Invisicare® technology, the company provides customized solutions for the individual needs of its customers. Avecho Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Avecho Biotechnology's EBIT
Avecho Biotechnology's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Avecho Biotechnology's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Avecho Biotechnology's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Avecho Biotechnology’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Avecho Biotechnology stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Avecho Biotechnology.
How has the EBIT of Avecho Biotechnology developed in recent years?
The EBIT of Avecho Biotechnology has increased by 43.945% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Avecho Biotechnology?
The EBIT of Avecho Biotechnology is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Avecho Biotechnology pay?
Over the past 12 months, Avecho Biotechnology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Avecho Biotechnology is expected to pay a dividend of 0 AUD.
What is the dividend yield of Avecho Biotechnology?
The current dividend yield of Avecho Biotechnology is .
When does Avecho Biotechnology pay dividends?
Avecho Biotechnology pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Avecho Biotechnology?
Avecho Biotechnology paid dividends every year for the past 0 years.
What is the dividend of Avecho Biotechnology?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Avecho Biotechnology located?
Avecho Biotechnology is assigned to the 'Health' sector.
Wann musste ich die Aktien von Avecho Biotechnology kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Avecho Biotechnology from 6/6/1997 amounting to 0.02 AUD, you needed to have the stock in your portfolio before the ex-date on 5/14/1997.
When did Avecho Biotechnology pay the last dividend?
The last dividend was paid out on 6/6/1997.
What was the dividend of Avecho Biotechnology in the year 2023?
In the year 2023, Avecho Biotechnology distributed 0 AUD as dividends.
In which currency does Avecho Biotechnology pay out the dividend?
The dividends of Avecho Biotechnology are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Avecho Biotechnology
Our stock analysis for Avecho Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Avecho Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Avecho Biotechnology Revenue
- Avecho Biotechnology Net Income
- Avecho Biotechnology P/E
- Avecho Biotechnology P/S
- Avecho Biotechnology EBIT
- Avecho Biotechnology Dividend
- Avecho Biotechnology Stocks
- Avecho Biotechnology Market capitalization
- Avecho Biotechnology Debt
- Avecho Biotechnology Liabilities
- Avecho Biotechnology Equity
- Avecho Biotechnology AAQS
- Avecho Biotechnology Employees
- Avecho Biotechnology ROE
- Avecho Biotechnology ROA
- Avecho Biotechnology ROCE
